Therapy of ankylosing spondylitis and other spondyloarthritides: Established medical treatment, anti-TNF-α therapy and other novel approaches

Arthritis Research

Volumn 4, Issue 5, 2002, Pages 307-321

  Braun, Juergen ^a   Sieper, Joachim ^b  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Ankylosing spondylitis; Anti TNF therapy; Conventional and innovative treatment; Psoriatic arthritis

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DICLOFENAC; ETANERCEPT; GLUCOCORTICOID; GOLD; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INFLIXIMAB; KETOPROFEN; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHENYLBUTAZONE; PIROXICAM; PLACEBO; RADIUM 224; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ANEMIA; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEMYELINATING DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEALTH CARE NEED; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INFECTION; LONG TERM CARE; LYMPHOMA; MALE; NEUROPATHY; PANCYTOPENIA; PSORIATIC ARTHRITIS; RADIODIAGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SPINE DISEASE; SPONDYLOARTHROPATHY; SYMPTOMATOLOGY; TREATMENT INDICATION; TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; DIPHOSPHONATES; GLUCOCORTICOIDS; GLUCOCORTICOIDS, SYNTHETIC; HUMAN; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036024683     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar592     Document Type: Review

References (163)

1. Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors
2. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: Many, but not all patients with sacroiliitis have spondyloarthropathy
3. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway
4. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Société de Rhumatologie de l'Ouest
5. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database
6. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients
7. Employment, work disability, and work days lost in patients with ankylosing spondylitis: A cross sectional study of Dutch patients
8. Work status and productivity costs due to ankylosing spondylitis: Comparison of three European countries
9. Health-related quality of life in ankylosing spondylitis: A survey of 175 patients
10. Assessment of fatigue in patients with ankylosing spondylitis: A psychometric analysis
11. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: A randomized controlled trial
12. Exercise in ankylosing spondylitis: How much is optimum?
13. Criteria for the classification of spondylarthropathies
14. Prognosis, course of disease, and treatment of the spondyloarthropathies
15. Predictive factors for the longterm outcome of spondyloarthropathies
16. Management of refractory ankylosing spondylitis and related spondyloarthropathies
17. A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis
18. Current guidelines for the drug treatment of ankylosing spondylitis
19. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial
20. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug
21. Pharmacological management of back pain syndromes
22. Low dose amitriptyline in ankylosing spondylitis: A short term, double blind, placebo controlled study
23. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study
24. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study
25. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial
26. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis
27. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis
28. Favorable results using methotrexate in the treatment of patients with ankylosing spondylitis
29. Methotrexate in severe ankylosing spondylitis: An open study
30. Efficacy of methotrexate in the treatment of ankylosing spondylitis: A three-year open study
31. Methotrexate in the treatment of ankylosing spondylitis
32. Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared to psoriatic arthritis and rheumatoid arthritis
33. Methotrexate in severe ankylosing spondylitis - A randomized placebo-controlled study
34. Treatment used by patients with with ankylosing spondylitis: Comparison with treatment preferences by rheumatologists
35. Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis
36. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis
37. Immunogenetics HLA-B27 and spondyloarthropathies
38. Enhanced expession of glucocorticoid receptor messenger RNA in peripheral blood mononuclear cells of patients with ankylosing spondylitis
39. Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells of patients with ankylosing spondylitis
40. Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis
41. The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis
42. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis
43. A case of HLA-B27 negative ankylosing spondylitis treated with methylprednisolone pulse therapy
44. The use of methylprednisolone pulse therapy in a severe case of HLA-B27 negative ankylosing spondylitis
45. Radiographic patterns and response to corticosteroid hip injection
46. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: A double-blind study
47. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: Clinical outcome and followup by dynamic magnetic resonance imaging
48. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy
49. Cancer mortality following X-ray treatment of ankylosing spondylitis
50. Leukemia mortality after X-ray treatment for ankylosing spondylitis
51. Managing seronegative spondarthritides
52. 224Ra
53. Late effects in ankylosing spondylitis patients treated with 224Ra
54. Therapy of ankylosing spondylitis with Radiumchloride
55. Effectiveness of lymphocytapheresis in a patient with ankylosing spondylitis
56. Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis
57. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients
58. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
59. An open study of pamidronate in the treatment of refractory ankylosing spondylitis
60. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy
61. Fracture risk in patients with ankylosing spondylitis: A population based study
62. A 6 month randomized double-blinded dose response comparison of i.v. pamidronate (60mg vs 10mg) in the treatment of NSAID-refractory ankylosing spondylitis (AS)
63. Thalidomide: Emerging role in cancer medicine
64. Thalidomide as an emerging immunotherapeutic agent
65. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis
66. A one year open label trial of thalidomide in ankylosing spondylitis
67. Identifying the targets of thalidomide and anti-TNFα antibody treatments in ankylosing spondylitis
68. Thalidomide treatment for refractory Crohn's disease: A review of the history, pharmacological mechanism and clinical literature
69. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
70. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
71. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
72. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
73. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease
74. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein
75. Infliximab and methotrexate in the treatment of rheumatoid arthritis
76. Enthesitis and ankylosis in spondyloarthropathy: What is the target of the immune response?
77. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients
78. Radiology and pathology of the spondyloarthropathies
79. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy
80. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis
81. T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies
82. Immunohistological study of entheses in spondyloarthropathies: Comparison in rheumatoid arthritis and osteoarthritis
83. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
84. HLA B27-related arthritis and bowel inflammation: Sulfasalazine in HLA B27-related arthritis
85. A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology
86. Anti-tumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety
87. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
88. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
89. Is infliximab effective for induction of remission in patients with ulcerative colitis?
90. Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms
91. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
92. Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation
93. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
94. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
95. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
96. A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index
97. Treatment of patients with severe ankylosing spondylitis with infliximab - A one year follow up
98. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study
99. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis
100. Infliximab in ankylosing spondylitis: A prospective observational inception cohort analysis of efficacy and safety
101. Efficacy of infliximab in severe refractory ankylosing spondylitis (AS). Results of an open label study
102. Successful treatment of active and refractory spondyloarthritis with the anti-TNFα monoclonal antibody infliximab
103. Infliximab in the treatment of spondylarthropathy, bone mineral density effect
104. Treatment of active ankylosing spondylitis with infliximab - A double-blind placebo controlled multicenter trial
105. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy
106. Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab
107. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept-A drug for refractory ankylosing spondylitis?
108. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study
109. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
110. Refractory inflammatory heel pain in spondyloarthropathy: A significant response to infliximab documented by ultrasound
111. Refractory inflammatory heel pain in spondyloarthropathy: A significant response to infliximab documented by ultrasound
112. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses
113. Methotrexate therapy for chronic noninfectious uveitis: Analysis of a case series of 160 patients
114. Infliximab in chronic uveitis
115. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease
116. Etanercept therapy in children with treatment-resistant uveitis
117. Infliximab in chronic uveitis
118. Anti-TNFα therapy with infliximab in the treatment of HLA B27 associated acute anterior uveitis - A one year follow up
119. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab
120. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
121. Tuberculosis and treatment with infliximab
122. Tuberculosis and treatment with infliximab
123. Tuberculosis and treatment with infliximab
124. Tuberculosis and treatment with infliximab
125. Structural deficiences in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol mycobacterium tuberculosis infection
126. Genetic influence on cytokine production and fatal meningococcal disease
127. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease
128. Viral pneumonia as a serious complication of etanercept therapy
129. Infliximab-induced aseptic meningitis
130. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept
131. Tuberculosis and treatment with infliximab
132. Invasive pulmonary aspergillosis associated with infliximab therapy
133. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with RA
134. Safety and efficacy of infliximab in 263 patients with active rheumatoid arthritis despite methotrexate therapy - A German open label trial
135. Experience with etanercept in an academic medical center: Are infection rates increased?
136. Tuberculosis and treatment with infliximab
137. Longterm safety and efficacy of etanercept in RA
138. Long-term follow-up of patients treated with Remicade (Infliximab) in clinical trials
139. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy
140. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides
141. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
142. Demyelinating and neurologic events reported in association with TNFα antagonism: By what mechanisms could TNFα antagonism improve RA but exacerbate multiple sclerosis?
143. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis
144. Leukocytoclastic vasculitis due to etanercept
145. Etanercept and infliximab associated with cutaneous vasculitis
146. Drug-induced systemic lupus erythematosus associated with etanercept therapy
147. The elevated ratio of interferon-γ/interieukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming beta
148. Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon-γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies
149. Crucial role of interleukin-10/interieukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis
150. Production, tissue distribution and function of IL-10 in psoriatic synovium
151. IL-10 plasma levels correlate with disease activity in spondyloarthropathy
152. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis
153. Low T cell production of TNFα and IFN-γ in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-308 gene polymorphism
154. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha
155. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: First clinical and laboratory experiences
156. Downregulation of the nonspecific and the antigen-specific T cell cytokine response in ankylosing spondylitis after treatment with infliximab
157. Cellular immune response to the cartilage-derived autoantigen G1 of aggrecan in ankylosing spondylitis and rheumatoid arthritis
158. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy. Histologic findings in eight patients from an open-label pilot study
159. Preliminary core sets for endpoints in ankylosing spondylitis
160. ASAS preliminary criteria for short term improvement in ankylosing spondylitis
161. Radiologic scoring methods in ankylosing spondylitis: Reliability and sensitivity to change over one year
162. The Bath Ankylosing Spondylitis Radiology Index (BASRI): A new, validated approach to disease assessment
163. Radiological outcome in ankylosing spondylitis: Use of the Stoke Ankylosing Spondylitis Spine Score (SASSS)